Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,670 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05170958RecruitingPhase 1/Phase 2
Study of LBL-024 for advanced cancers
This trial tests LBL-024 in people with advanced cancer to see how it works and how safe it is. You may consider it if you are well enough for study visits and have time to complete at least about 12 weeks of follow-up.
Hefei, AnhuiAges 18–80 - NCT05057845RecruitingPhase 2
Freezing treatment plus immunotherapy and a pill for liver cancer
This trial tests whether freezing (cryoablation) combined with tislelizumab and lenvatinib can help shrink advanced liver cancer and improve outcomes after earlier treatments stopped working or caused side effects. It may be an option if your cancer can’t be removed with surgery and you’ve already tried one prior systemic (whole-body) treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05038150RecruitingPhase 1/Phase 2
Early-stage drug study for advanced cancers that stopped responding
This Phase 1/2 trial tests SGN1 in people with advanced solid tumors whose cancer has grown despite standard treatments, or who could not tolerate them. The study aims to find a safe dose and see whether the drug can work in certain cancer types.
Gilbert, ArizonaAges 18–75 - NCT04866641RecruitingPhase 1
Early safety study of T-1201 for advanced solid tumors
This Phase 1 study tests how safe T-1201 (an injection) is in people with advanced solid tumors that are not responding to standard treatment. It mainly looks at side effects and tolerability, and it may offer a treatment option if other options are no longer working.
Kaohsiung CityAges 20 years+ - NCT04740398RecruitingPhase 1
CBP-1008 for advanced solid tumors that standard therapy failed
This Phase 1 study tests CBP-1008, a new experimental treatment, in people with advanced solid cancers that either worsened after standard treatment or for which no standard option exists. It may help doctors learn the safest dose and whether it shows signs of benefit in specific tumor types.
Beijing, Beijing MunicipalityAges 18–70 - NCT05245058RecruitingEarly Phase 1
SPH5030 for HER2-positive advanced solid tumors
This early-stage study tests SPH5030 tablets in people with HER2-positive advanced solid tumors that have not responded to standard treatment or have no standard option. It aims to see whether the treatment can shrink tumors and is safe enough to move forward.
Hefei, AnhuiAges 18 years+ - NCT05103345RecruitingPhase 1/Phase 2
Injection into tumors to treat advanced solid cancers
This early-phase study tests a medicine called SGN1 given directly into a solid tumor. It’s for people with advanced cancers that have not responded to standard treatment (or don’t have good standard options) and aims to see if the injection is safe and may work.
Guangzhou, GuangdongAges 18–75 - NCT05263479RecruitingPhase 1
Study drug for advanced solid tumors that can’t be treated
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05142423RecruitingPhase 1/Phase 2
First study of AK109 plus AK104 for advanced solid cancers
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
Hangzhou, ZhejiangAges 18–75 - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
San Francisco, CaliforniaAges 6 months–25 years - NCT05098184RecruitingEarly Phase 1
Study TIL treatment for advanced melanoma using harvested tumor cells
This early-phase trial tests GC101 TIL, a treatment made from your own melanoma tumor cells, for advanced melanoma. It may help the immune system better fight the cancer after standard treatments have already stopped working or if none are available.
ShanghaiAges 18–75 - NCT04966481RecruitingPhase 3
Palbociclib plus cetuximab versus cetuximab alone
This trial studies whether adding palbociclib to cetuximab works better than cetuximab by itself for head and neck cancer that is growing again after an anti–PD-1/PD-L1 treatment. It is for people whose tumor has a specific gene change (CDKN2A loss) and who have not had too many prior treatments.
Worthington, MinnesotaAges 18 years+ - NCT04481932RecruitingPhase 2
Trastuzumab with chemo for HER2-positive breast cancer
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT04144569RecruitingPhase 2
PD-1 plus pyrotinib for HER2-mutated lung cancer after chemo
This trial tests a combination treatment—PD-1 plus pyrotinib—in people with advanced lung cancer that has a specific HER2 “insertion” genetic change. It may help if your first standard chemotherapy did not work and you still have measurable tumors to track.
Changsha, HunanAges 18–75 - NCT04387916RecruitingPhase 1
Test drug KC1036 in people with advanced solid tumors
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT05547321RecruitingPhase 1
New cancer drug plus immunotherapy for advanced solid tumors
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
Boston, MassachusettsAges 18 years+ - NCT05263960RecruitingPhase 1/Phase 2
CM350 drug study for advanced solid tumors
This trial tests CM350 in people with advanced solid cancers that are hard to treat with standard options. It may help by finding a safe dose and whether the drug can work against these cancers.
Chengdu, SichuanAges 18–75 - NCT05098171RecruitingEarly Phase 1
Study TIL cell therapy for advanced gynecologic cancers
This early-phase study tests GC201 TIL therapy, made from your tumor’s immune cells (TILs), for advanced or returning gynecologic cancers. If standard treatments have already failed—or there aren’t standard options—this trial may offer a new way to train your immune system to fight the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04093466RecruitingPhase 1
Testing a new pill for advanced solid tumors
This Phase 1 trial tests kanitinib (CX1003), a new cancer medicine, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The goal is to find a safe dose and see early signs of tumor response.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05067283RecruitingPhase 1
Study of Calderasib for KRAS G12C advanced cancers
This trial tests a new drug, Calderasib, for people with advanced solid tumors that have a specific mutation called KRAS G12C. It may help if your cancer has not responded to previous treatments or if you have certain types of lung or colorectal cancer.
Tampa, FloridaAges 18 years+ - NCT05645276RecruitingPhase 1
Study of AK129 for advanced solid tumors
This Phase 1 study tests AK129 in people with advanced cancers that have spread. It looks for a safe dose and early signs the treatment may work, especially for tumors with measurable disease and needed prior treatment options.
Beijing, Beijing MunicipalityAges 18–75 - NCT06947291RecruitingPhase 2
Study of glumetinib plus nab-docetaxel for advanced stomach cancer
This trial tests a combination of two drugs, glumetinib and nab-docetaxel, in people with advanced stomach cancer or other solid tumors that have a specific change in the MET gene. The goal is to see if this combination is safe and works better than current treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06257680RecruitingPhase 1
ReT01 cell therapy for advanced solid tumors
This trial tests a new cell therapy called ReT01 for people with advanced solid tumors that have stopped responding to standard treatments. It uses your own immune cells from a tumor sample to fight the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06157827RecruitingPhase 1/Phase 2
Testing LBL-024 plus chemo for advanced neuroendocrine carcinoma
This trial tests a new drug, LBL-024, combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma. The goal is to see if this combination works better than chemo alone.
Hefei, AnhuiAges 18–75
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,670 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.